Hand eczema and temporal variation of Staphylococcus aureus clonal complexes: A prospective observational study.

Bookmark this %label%

Hand eczema (HE) is frequently colonized with Staphylococcus aureus (S. aureus); however, its role in the pathogenesis of HE is poorly understood.To investigate temporal variation of S. aureus sub-types, i.e. […]

» Read more

The cardiovascular safety of oral alitretinoin. A population-based cohort study involving 19,513 patients exposed to oral alitretinoin.

Bookmark this %label%

Oral alitretinoin is a retinoid used for severe chronic hand eczema. Although caution is recommended for patients with uncontrolled dyslipidaemia or cardiovascular risk factors, the actual atherothrombotic risk has not […]

» Read more

Inflammatory Skin Diseases and the Risk of Chronic Kidney Disease – Population-Based Case-control and Cohort analyses.

Bookmark this %label%

Emerging evidence suggests an association between common inflammatory skin diseases and chronic kidney disease (CKD).To explore the association between CKD stages 3-5 and atopic eczema, psoriasis, rosacea, and hidradenitis suppurativa.We […]

» Read more

Dupilumab treatment in atopic dermatitis patients in the Netherlands versus Japan: a comparative cohort study revealing a discrepancy in patient-reported outcome measures.

Bookmark this %label%

Dupilumab was equally effective among all racial subgroups in clinical trials, but a direct comparison in daily practice is lacking.To investigate effectiveness of dupilumab in atopic dermatitis (AD) patients in […]

» Read more

Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy Phase 3 trial in the United States and Canada (BREEZE-AD5).

Bookmark this %label%

Baricitinib, an oral, selective Janus kinase (JAK)1/JAK2 inhibitor, is being studied for moderate-to-severe atopic dermatitis (AD) in adults.To evaluate the efficacy and safety of baricitinib monotherapy in a North American […]

» Read more

Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting.

Bookmark this %label%

The Harmonising Outcome Measures for Eczema (HOME) initiative has established a core outcome set of domains for atopic eczema (AE) clinical trials. Previous consensus meetings have agreed on preferred instruments […]

» Read more

Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis.

Bookmark this %label%

Antibody-based therapies that inhibit pro-inflammatory cytokine signaling are commonly used in dermatology. Paradoxically, these medications may induce or exacerbate inflammatory disorders.To summarize the spectrum of manifestations, incidence, timing, potential mechanisms, […]

» Read more

Hand Dermatitis in Adults Referred for Patch Testing: Analysis of North American Contact Dermatitis Group Data, 2000-2016.

Bookmark this %label%

Hand eczema (HE) is a heterogeneous and burdensome disorder.To characterize the clinical characteristics, etiologies and allergen relevance in adults with HE referred for patch testing.Retrospective analysis (2000-2016) of North American […]

» Read more

Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting.

Bookmark this %label%

The Harmonising Outcome Measures for Eczema (HOME) initiative has established a core outcome set of domains for atopic eczema clinical trials. Previous consensus meetings have agreed upon preferred instruments for […]

» Read more

Risk of Skin Disorders in Patients with Celiac Disease: A Population-Based Cohort Study.

Bookmark this %label%

Although dermatitis herpetiformis is closely associated with celiac disease (CD), data on the relationship between CD and other dermatologic disorders have been mixed. We aimed to quantify the risk of […]

» Read more

Measurement properties of the Patient-Reported Outcomes Information System (PROMIS® ) Itch Questionnaire: itch severity assessments in adults with atopic dermatitis.

Bookmark this %label%

Itch is the most common and burdensome symptom of atopic dermatitis (AD, also simply known as eczema). However, there is limited data to support the validity of different approaches to […]

» Read more

Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis: A single centre, prospective one-year observational cohort study of the first 100 patients treated.

Bookmark this %label%

Dupilumab (Dupixent®) is the first biologic drug licensed for treatment of adults with atopic dermatitis (AD). Data regarding its long-term real-world effectiveness and tolerability are limited. We report comprehensive outcome […]

» Read more

“Fake news” in dermatology. Results from an observational, cross-sectional study.

Bookmark this %label%

Social networks have become a means for disseminating information on health-related matters.Describe the characteristics and analyze the accuracy of the dermatology content that is most often shared on the most […]

» Read more

Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).

Bookmark this %label%

Tralokinumab, a fully human monoclonal antibody, specifically neutralizes interleukin-13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In phase II studies, tralokinumab combined with topical corticosteroids provided early […]

» Read more

Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.

Bookmark this %label%

Tralokinumab is a fully human monoclonal antibody that specifically neutralizes interleukin-13, a key driver of atopic dermatitis (AD).To evaluate the efficacy and safety of tralokinumab in combination with TCS in […]

» Read more

Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis.

Bookmark this %label%

Atopic dermatitis (AD) is an allergic disease that affects individuals of various ages. Recently, the IL-4/13 inhibitor dupilumab has gained regulatory approval for clinical use in AD patients. Dupilumab has […]

» Read more

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study.

Bookmark this %label%

Children aged ≥6 to <12 years with severe atopic dermatitis (AD) have limited treatment options. In a 16-week, randomized, placebo-controlled, phase III trial in children, dupilumab, a monoclonal antibody inhibiting […]

» Read more

What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study.

Bookmark this %label%

Multiple strategies have been used to evaluate the minimal important change (MIC) of the Eczema Area and Severity Index (EASI) and Scoring Atopic Dermatitis (SCORAD). The meaningfulness of these MICs […]

» Read more

What’s new in atopic eczema? An analysis of systematic reviews published in 2018. Part 1: prevention and topical therapies.

Bookmark this %label%

This review is part of a series of annual updates that summarize the evidence base for atopic eczema (AE). The aim is to provide a succinct guide for clinicians on […]

» Read more

Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis.

Bookmark this %label%

Dupilumab, the first biological drug to be approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adolescents and adults has shown good efficacy and safety in clinical trials.To evaluate […]

» Read more
1 2 3